Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Dark Horse Consulting Group (DHC), based in Walnut Creek, Calif., submitted proposed draft guidance to the FDA for gene therapy safety.
CRISPR Therapeutics tapped Amgen veteran Phuong Khanh (P.K.) Morrow, M.D., FACP, as its new chief medical officer.
COVID-19 would have claimed over 110,000 more lives in 2021 if vaccines weren’t available, according to a Pfizer-sponsored report on the first year of the U.S. vaccination program.
The ASGCT’s 25th Annual Meeting features the latest scientific research in genetics and cellular therapies. Read on for highlights from the meeting.
Evotec and Sernova partnered to develop an implantable induced pluripotent stem cell (iPSC)-based beta cell replacement therapy that can be used to treat both type 1 and 2 diabetes patients.
Researchers continue to explore how to turn deadly venom into life-saving drugs. Several papers on the subject have recently been published and BioSpace is taking a look at them.
During the past several years, data generation, data mining and analytics have progressed to the point that it is now possible to bring precision medicine to psychiatry.
Agios Pharmaceuticals is cutting its staff numbers by 50 as part of plans to lay low on exploratory research efforts to focus on the success of late-stage initiatives.
Cugene and AbbVie came together on autoimmune diseases and cancer, while Proteros and AstraZeneca expanded their collaboration on epigenetic cancer drugs.
In honor of ALS Awareness Month, BioSpace spoke with leading researchers like Dr. Matthew Harms of Columbia University and Drs. Howard Berman and Stanley Appel at Coya Therapeutics.
Sofinnova Partners announced on Monday that it entered into a long-term strategic and financial partnership with Apollo to expand its presence in the life sciences.
Orna announced first-ever data from its lead isCAR program that validates both the technology and its LNP delivery platform. BioSpace spoke with ORNA CEO Tom Barnes.
PRESS RELEASES
Head-to-Head Study Highlights Rocbrutinib as the World’s First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations
Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations